Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 8belzutifan 7pembrolizumab 6Ipilimumab 5cabozantinib 3Surveys and Questionnaires 3lenvatinib 2Radiosurgery 2Paclitaxel 2Everolimus 2Carboplatin 2pazopanib 1palbociclib 1liposomal doxorubicin 1guadecitabine 1fludarabine phosphate 1endothelial PAS domain-containing protein 1 1durvalumab 1cemiplimab 1atezolizumab 1aldesleukin 1X-Rays 1Technetium Tc 99m Sestamibi 1Taxes 1Sunitinib 1Spermine Synthase 1Social Determinants of Health 1Single Photon Emission Computed Tomography Computed Tomography 1Radiotherapy 1Radionuclide Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Kidney Neoplasms × PT2385 × Clear all
NCT02293980 2024-06-17

MK-3795-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting
110 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡